POT1 clinical risk management is an open question

Mandy L Ballinger^{1

2

3}, David M Thomas^{4

5

6}

Affiliations

¹ Genomic Cancer Medicine Laboratory, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia. mandy.ballinger@unsw.edu.au.
² Centre for Molecular Oncology, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia. mandy.ballinger@unsw.edu.au.
³ Omico, Kensington, NSW, Australia. mandy.ballinger@unsw.edu.au.
⁴ Genomic Cancer Medicine Laboratory, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
⁵ Centre for Molecular Oncology, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia.
⁶ Omico, Kensington, NSW, Australia.

Comment

Mandy L Ballinger et al. Eur J Hum Genet. 2025 Jan.

. 2025 Jan;33(1):3-4.

doi: 10.1038/s41431-024-01676-x. Epub 2024 Aug 13.

Mandy L Ballinger^{1

2

3}, David M Thomas^{4

5

6}

¹ Genomic Cancer Medicine Laboratory, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia. mandy.ballinger@unsw.edu.au.
² Centre for Molecular Oncology, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia. mandy.ballinger@unsw.edu.au.
³ Omico, Kensington, NSW, Australia. mandy.ballinger@unsw.edu.au.
⁴ Genomic Cancer Medicine Laboratory, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
⁵ Centre for Molecular Oncology, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia.
⁶ Omico, Kensington, NSW, Australia.

No abstract available

Conflict of interest statement

Competing interests: The authors declare no competing interests.

POT1 tumour predisposition: a broader spectrum of associated malignancies and proposal for additional screening program.
Baptista Freitas M, Desmyter L, Badoer C, Smits G, Vandernoot I, T Kint de Roodenbeke D. Baptista Freitas M, et al. Eur J Hum Genet. 2024 Aug;32(8):980-986. doi: 10.1038/s41431-024-01611-0. Epub 2024 Jun 5. Eur J Hum Genet. 2024. PMID: 38839987 Free PMC article.

1. Baptista Freitas M, Desmyter L, Badoer C, Smits G, Vandernoot I, T’Kint de Roodenbeke D. POT1 tumour predisposition: a broader spectrum of associated malignancies and proposal for additional screening program. Eur J Hum Genet. 2024. 10.1038/s41431-024-01611-0. - PMC - PubMed
1. Robles-Espinoza CD, Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, et al. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet. 2014;46:478–81. - PMC - PubMed
1. Herrara-Mullar J, Fulk K, Brannan T, Yussuf A, Polfus L, Richardson ME, et al. Characterisation of POT1 tumor predisposition syndrome: tumor prevalence in a clinically diverse hereditary cancer cohort. Genet Med. 2023;25:100937. - PubMed
1. DeBoy EA, Tassia MG, Schratz KE, Yan SM, Cosner ZL, McNally EJ, et al. Familial clonal hematopoiesis in a long telomere syndrome. N Engl J Med. 2023;388:2422–33. - PMC - PubMed
1. Henry M-L, Osborne J, Else T. POT1 tumor predisposition. Gene Rev. 2022. https://www.ncbi.nlm.nih.gov/books/NBK563529/